ATEC
The back straightening act
Alphatec is trying to do what every growthy medtech story eventually has to do: stop living on vibes and start living on math. The company says revenue grew 15%, operating leverage improved, and free cash flow finally turned positive — the kind of combo that makes investors sit up a little straighter too.
Guidance that says “we’re not bluffing”
Management kept sales guidance parked at $882 million, but lifted adjusted EBITDA guidance to $140 million. Translation: the top line is still doing its job, and the company believes more of each dollar is starting to stick around instead of disappearing into the cost machine.
That matters because Alphatec has had the usual growing-company baggage: ongoing net losses, dilution, and leverage worries. Those clouds haven’t vanished, but they’re looking less thunderstorm-y if free cash flow is positive, dilution is slowing, and interest expense is coming down.
Why investors care
The sneaky important detail here is the EOS imaging technology growth. That’s the sort of operational engine that can help Alphatec look less like a science experiment and more like a business that might actually make it to the promised land.
Big picture: this is still a company in the messy middle, but the latest update suggests Alphatec is at least moving from "please be patient" mode toward "okay, maybe the turnaround is real."